---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216821"
form_type: "8-K"
ticker: "CBLL"
cik: "0001861107"
company_name: "Ceribell, Inc."
filed_at: "2026-05-11T20:16:47+00:00"
generated_at: "2026-05-11T20:19:48.347802+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ceribell Q1 revenue $26.5M (+29% YoY); raises FY2026 guidance to $112-116M

## Summary
- Revenue $26.5M, up 29% YoY; product $20.2M, subscription $6.3M, both +29%.
- Net loss $19.7M ($0.52/sh) vs $12.8M ($0.36) YoY; adj. EBITDA loss $11.2M.
- Launched neonate/pediatric EEG products; 680 active accounts at quarter end.
- CMS proposed rule for NTAP reimbursement for delirium monitoring; final rule Aug 2026.
- FY2026 revenue guidance raised to $112-116M (26-30% growth); cash $141.2M.

## SEC filing metadata
- accession: 0001193125-26-216821
- form_type: 8-K
- ticker: CBLL
- cik: 0001861107
- company_name: Ceribell, Inc.
- filed_at: 2026-05-11T20:16:47+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861107/000119312526216821/0001193125-26-216821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861107/000119312526216821/cbll-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216821
- JSON: https://secwatch.observer/filing/0001193125-26-216821.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216821.txt

## Key facts
- Earnings Releases
  Ceribell, Inc. reported first quarter ended March 31, 2026 results: revenue $26.5 million, net income $19.7 million, EPS $0.52 net loss per share. Guidance raised.
  - Period: first quarter ended March 31, 2026
  - Revenue: $26.5 million
  - Net income: $19.7 million
  - EPS: $0.52 net loss per share
  - Guidance: raised
  - Result: reported results
  source text: serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 & Recent Highlights • Reported total revenue of $26.5 million in the first quarter of 2026, a 29% increase compared to the same period in 2025 • Ended the quarter with 680 total active accounts • Achieved gross margin of 87% • Initiated
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861107/000119312526216821/0001193125-26-216821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.